ClinicalTrials.gg
CompletedNCT00253786Updated Jul 23, 2019

Study for the Effectiveness of Intensive Therapy Aiming at a Remission of Diabetic Nephropathy

An interventional study of Intensive multifactorial therapy and Standard therapy in Type 2 Diabetes Mellitus and Diabetic Nephropathy, sponsored by Okayama University. Completed at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-23.

Sponsored by Okayama University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 394 studies in Diabetes Mellitus, Type 2 with a site in Japan — 23 open to participants now, 31 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Japan.

Enrollment
154th of 334
312 · median 284
Started
2005
with 2 others
No phase
17 of 394
none open now
Registered
12th of 394
by date

Among the 394 studies in Diabetes Mellitus, Type 2 with a site in Japan, this one is the 154th largest by enrollment of the 334 interventional ones that give a count, is one of 3 that started in 2005, is one of 17 with no phase, and was the 12th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

23 of the 394 studies in Diabetes Mellitus, Type 2 with a site in Japan are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 394 studies in Diabetes Mellitus, Type 2 with a site in Japan, or all of them as a file.
02

Study summary

Study for the effectiveness of intensive therapy aiming at the remission of diabetic nephropathy

Read the detailed description

Study for the effectiveness of intensive therapy for diabetic nephropathy in unblinded, randomized intergroup comparison study.

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Diabetic Nephropathy

Keywords

  • diabetes
  • nephropathy
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with type 2 diabetes
  2. Urinary albumin-to-creatinine ratio: >=300 mg/g creatinine twice in the first morning urine sample
  3. Serum creatinine level: =\<2.5 mg/dl
  4. Patients aged 20-75 years

Exclusion criteria

Exclusion Criteria:

  1. Type 1 diabetes
  2. Hereditary diabetes or secondary diabetes
  3. Non-diabetic nephropathy
  4. Familial hypercholesterolemia
  5. Secondary hypertension
  6. Unstable angina pectoris or history of myocardial infarction/stroke within 6 months prior to consent acquisition
  7. Malignant tumor or life threatening disease
  8. History of angioedema
  9. Patients undergoing LDL apheresis
  10. Biliary system obstruction or severe liver injury
  11. Liver dysfunction
  12. Allergy for ACE-Is, ARBs or HMG-CoA reductase inhibitors
  13. Pregnant or nursing patients
  14. Others: patients who are not suitable for this trial
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
312 participants (actual)

Study arms

  • Experimental
    Intensive multifactorial therapy (Protocol A)

    Protocol A: serum creatinine \<1.2 mg/dl in male and \<1.0 mg/dl in female.

    Other: Intensive multifactorial therapy

  • Active comparator
    Standard therapy (Protocol A)

    Protocol A: serum creatinine \<1.2 mg/dl in male and \<1.0 mg/dl in female.

    Other: Standard therapy

  • Experimental
    Intensive multifactorial therapy (Protocol B)

    Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.

    Other: Intensive multifactorial therapy

  • Active comparator
    Standard therapy (Protocol B)

    Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.

    Other: Standard therapy

Interventions

  • OtherIntensive multifactorial therapy

    Blood glucose control: HbA1c \< 6.2% Blood pressure control: SBP \< 125 mmHg, DBP: \< 75 mmHg Lipid profile: T-cho \< 180 mg/dl, LDL-cho \< 100 mg/dl, HDL-cho \>40 mg/dl Dietary intervention: TDEI \< 30 kcal/kg/day, sodium \< 5 g/day, protein \< 0.8 g/kg/day Pharmacological intervention: ACE-Is or ARBs, HMG-CoA reductase inhibitors, multivitamins Instruction by co-medicals: Taking medicines, smoking cessation, nutrition care

  • OtherStandard therapy

    Blood glucose control: HbA1c \< 6.9% Blood pressure control: SBP \< 130 mmHg, DBP: \< 80 mmHg Lipid profile: T-cho \< 200 mg/dl, LDL-cho \< 120 mg/dl, HDL-cho \>40 mg/dl, Dietary intervention: TDEI \< 25-30 kcal/kg/day, sodium \< 6 g/day, protein \< 1.0 g/kg/day Pharmacological intervention: No restrictions (continuing prior therapy) Instruction by co-medicals: No restrictions (continuing prior therapy)

06

What researchers measure

Primary outcomes

  1. Urinary protein/creatinine ratio (in the first morning urine sample) in Protocol A

    Time frame: 5 years

  2. Composite endpoint of time to first occurrence of (1) Doubling of serum creatinine, (2) Need for chronic dialysis or renal transplantation, or (3) Death in Protocol B

    Time frame: 5 years

Secondary outcomes

  1. GFR in Protocol A

    Time frame: 5 years

  2. Cardiovascular event in Protocol A

    Time frame: 5 years

  3. Progression of retinopathy in Protocol A

    Time frame: 5 years

  4. Urinary albumin/creatinine ratio in Protocol A

    Time frame: 5 years

  5. Proteinuria (24 h collection sample) in Protocol A

    Time frame: 5 years

  6. GFR in Protocol B

    Time frame: 5 years

  7. Cardiovascular event in Protocol B

    Time frame: 5 years

  8. Progression of retinopathy in Protocol B

    Time frame: 5 years

  9. Urinary albumin/creatinine ratio in Protocol B

    Time frame: 5 years

  10. Urinary protein/creatinine ratio in Protocol B

    Time frame: 5 years

07

Study locations

1 site
  • Okayama University Hospital
    Okayama, 700-8558, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2005 to primary completion in Nov 2014, 108 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 108 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2005
First posted
Nov 15, 2005
StartActual
Nov 11, 2005
Primary completionActual
Nov 27, 2014
CompletionActual
Nov 27, 2014
Last update
Jul 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00253786
Lead sponsor
Okayama University
Responsible party
Kenichi Shikata (Professor, Okayama University) — Principal investigator
First posted
Nov 15, 2005
Start date
Nov 11, 2005
Primary completion
Nov 27, 2014
Completion
Nov 27, 2014
Last update
Jul 23, 2019

Study contacts

Hirofumi Makino, M.D.
principal investigator · Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion